Table 1.
Baseline characteristics of the study participants after propensity score matching (n = 465).
| CGM non-users (n = 310) | CGM users (n = 155) | P-value | |
|---|---|---|---|
| Age, years | 43.4 ± 16.6 | 43.5 ± 13.6 | 0.954 |
| Female, % | 165 (53.2%) | 86 (55.5%) | 0.717 |
| Duration of diabetes, years | 13.7 ± 9.5 | 10.9 ± 8.6 | 0.002 |
| Total daily dose of insulin, units | 45.2 ± 25.1 | 40.4 ± 22.0 | 0.042 |
| Hemoglobin A1c, % | 7.5 ± 1.2 | 7.5 ± 1.2 | 0.85 |
| BMI, kg/m2 | 23.2 ± 3.8 | 22.7 ± 3.1 | 0.143 |
| eGFR, ml/min/1.73 m2 | 94.0 ± 28.3 | 98.1 ± 24.4 | 0.112 |
| ALT, U/L | 21.3 ± 14.7 | 21.3 ± 16.8 | 0.988 |
| AST, U/L | 24.1 ± 14.8 | 24.4 ± 21.5 | 0.892 |
| Total cholesterol, mg/dl | 158.9 ± 35.4 | 172.3 ± 88.1 | 0.071 |
| HDL cholesterol, mg/dl | 64.0 ± 18.7 | 68.8 ± 17.4 | 0.007 |
| LDL cholesterol, mg/dl | 94.3 ± 34.5 | 95.7 ± 33.1 | 0.685 |
| TG, mg/dl | 95.6 ± 60.3 | 84.3 ± 45.1 | 0.023 |
| Insulin regimen (%) | 0.064 | ||
| Multiple daily injections | 283 (91.3%) | 149 (96.1%) | |
| Mixpen analogs | 9 (2.9%) | 0 (0%) | |
| Continuous subcutaneous insulin infusion | 18 (5.8%) | 6 (3.9%) | |
| Type of CGM (%) | – | ||
| Abbott Freestyle Libre | – | 25 (16.1%) | |
| Dexcom G5 | – | 100 (64.5%) | |
| Dexcom G6 | – | 15 (9.7%) | |
| Medtronic Guardian Connect | – | 15 (9.7%) |
Data are expressed as mean ± standard deviation (SD) or n (%).
ALT, alanine aminotransferase; AST, aspartate aminotransferase; BMI, body mass index; CGM, continuous glucose monitoring; eGFR, estimated glomerular filtration rate; HDL, high-density lipoprotein; LDL, low-density lipoprotein; SD, standard deviation; TG, triglyceride.